Panel Says to Keep Saccharin an ‘Anticipated’ Carcinogen

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

RESEARCH TRIANGLE PARK, North Carolina-Saccharin just missed winning a reprieve. By a 4-to-3 vote, an advisory panel recommended that the federal government continue to list the artificial sweetener as “reasonably anticipated to be a human carcinogen.”

RESEARCH TRIANGLE PARK, North Carolina—Saccharin just missed winning a reprieve. By a 4-to-3 vote, an advisory panel recommended that the federal government continue to list the artificial sweetener as “reasonably anticipated to be a human carcinogen.”

The board of scientific counselors of the National Toxicology Program also recommended that the 9th edition of the federal “Report on Carcinogens” list ultraviolet light as a known human carcinogen, whether the source is sunlight or a tanning bed or booth.

Working under new rules that permit the listing of chemical mixtures as well as single chemicals, the board further urged that smokeless tobacco and inhaled tobacco smoke be added to the list of “known” human carcinogens. Certain chemicals present in tobacco and tobacco smoke already carry the “known” designation. The advisory group, however, sought to emphasize that tobacco products as a whole, whether smoked, chewed, or snorted, can cause cancer in humans.

Although the board recommended listing of the antiestrogen tamoxifen (Nolvadex) as a known human carcinogen, it also strongly emphasized that the drug’s benefits in preventing breast cancer recurrence greatly outweigh its risks.

In its saccharin decision, the board rejected the advice of the scientific review committees of the National Institute of Environmental Health Sciences and the Interagency Committee Working Group for the Report on Carcinogens. Saccharin was labeled an “anticipated” carcinogen in 1981 on the basis of animals studies, including a 1977 Canadian rat study.

Among the other recommendations:

  • Add to the list of known human carcinogens benzidine dyes, used in textiles, paper, and leather, and strong inorganic acid mists containing sulfuric acid, used in making fertilizers, explosives, and plastics, and in petroleum refining.
  • Raise from “anticipated” to “known” carcinogen, cadmium, used in batteries; 1,3-butadiene, used in making synthetic rubber; and dioxin, an impurity formed in herbicide manufacture, incineration, and several industrial processes.
  • Add as “anticipated” carcinogens trichloroethylene, an industrial solvent once used to decaffeinate coffee; chloroprene, used in industrial rubber products and in adhesives in food packaging; and phenolphthalein, an ingredient once used in nonprescription laxatives.
Recent Videos
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Related Content